Fully human protein
Low immunogenicity
Does not bind compliment and is not associated with compliment mediated cell lysis.
Dosing schedule maintains stable serum concentrations, coadministration with methotrexate does not modify etanercept pharmacokinetics
No pharmacokinetic interaction with methotrexate
Lower the risk of TB
Lower the treatment discontinuation rate
Longest drug survival times
Lowers the risk of infections
Safe and well tolerated